The Effects of Estradiol Valerate 2 mg and Dienogest 2 mg Combination on Activated Protein C Resistance in Healthy Postmenopausal Women

Basit Öğe Kaydı
dc.contributor.authorKafkas, Samet
dc.contributor.authorKalkan, Nurdan Yidiz
dc.contributor.authorBolaman, Zahit
dc.contributor.authorKalkan, Uzeyir
dc.contributor.authorOdabasi, Ali R. Za
dc.contributor.authorYuksel, Hasan
dc.contributor.authorBatun, Sabri
dc.date.accessioned2024-04-24T17:38:23Z
dc.date.available2024-04-24T17:38:23Z
dc.date.issued2006
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: It is aimed that, to investigate the effect of estradiol valerate and dienogest combination, which is used as a hormone replacement therapy (HRT) regimen on hemostatic parameters and activated Protein C resistance in healthy postmenopausal women. Materials and Methods: Fifty seven women received HRT treatment in four month period. The placebo group consisted of 50 women. In the HRT group 10.5% (6/57), and in the placebo group 4% (2/50) were heterozigot of FV Leiden mutation. Hemostatic parameters were investigated in only non-mutation women, to avoid potential effects of FV Leiden mutation on activated Protein C. Results: Although these changes did not reach statistical significance, a comparison of hemostatic parameters for both groups showed that in the study group (receiving 2 mg EV/2 mg DNG) FV and Protein C levels were increased, and FVIII levels were decreased compared to the placebo group. There were also no significant differences in FVII and free Protein S levels. Multiple logistic regression analysis was performed to determine the association of (2 mg EV/2 mg DNG) treatment with FV, FVII, FVIII, Protein C, free Protein S and activated Protein C sensitivity rate. There was no significant effect of these independent variables on activated Protein C sensitivity rate (p>0.05). Discussion: Combination of estradiol valerate and dienogest has no effect on activated Protein C sensitivity ratios. Hormone replacement therapy does not cause acquired activated Protein C resistance (p>0.05).en_US
dc.identifier.endpage341en_US
dc.identifier.issn1309-0399
dc.identifier.issn1309-0380
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-33846384588
dc.identifier.scopusqualityQ3
dc.identifier.startpage334en_US
dc.identifier.urihttps://hdl.handle.net/11468/21429
dc.identifier.volume7en_US
dc.identifier.wosWOS:000420577200011
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isotren_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofJournal of The Turkish-German Gynecological Association
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMenopauseen_US
dc.subjectHormone Therapyen_US
dc.subjectActivated Protein C Resistanceen_US
dc.subjectHaemostasisen_US
dc.titleThe Effects of Estradiol Valerate 2 mg and Dienogest 2 mg Combination on Activated Protein C Resistance in Healthy Postmenopausal Womenen_US
dc.titleThe Effects of Estradiol Valerate 2 mg and Dienogest 2 mg Combination on Activated Protein C Resistance in Healthy Postmenopausal Women
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu